CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer.
2/5 보강
OpenAlex 토픽 ·
Advanced Breast Cancer Therapies
Cancer-related Molecular Pathways
Hedgehog Signaling Pathway Studies
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[BACKGROUND] Hormone receptor-positive (HR + ), HER2-negative breast cancer comprises ~70% of all breast cancer cases and is primarily treated with endocrine therapies such as tamoxifen, aromatase inh
- 표본수 (n) 138
APA
Suhail Ahmad, Ashwin Butle, et al. (2026). CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer.. British journal of cancer. https://doi.org/10.1038/s41416-026-03388-z
MLA
Suhail Ahmad, et al.. "CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer.." British journal of cancer, 2026.
PMID
42020778 ↗
Abstract 한글 요약
[BACKGROUND] Hormone receptor-positive (HR + ), HER2-negative breast cancer comprises ~70% of all breast cancer cases and is primarily treated with endocrine therapies such as tamoxifen, aromatase inhibitors, fulvestrant, and CDK4/6 inhibitors. However, resistance arises in ~40% of patients, limiting therapeutic efficacy.
[METHOD] We performed integrated genomic, transcriptomic, and functional analyses of 186 HR + /HER2-tumors (88 sensitive, 98 resistant), to identify key drivers of endocrine hormone therapy resistance, Findings were validated functionally using in-vitro and in-vivo models.
[RESULTS] We identify frequent CDKN1B (p27) loss-of-function mutations or deletions as a key and clinically actionable driver of endocrine resistance. CDKN1B knockdown in cell lines induces resistance to tamoxifen and fulvestrant, while its restoration re-sensitizes resistant cells. Importantly, CDKN1B-deficient tumors remain responsive to CDK4/6 inhibition, in vitro and in vivo. Immunohistochemistry and transcriptomic analysis of clinical cohorts (n = 138) and TCGA-METABRIC data (n = 1398) identify low p27 as an independent predictor of early relapse and poor survival.
[CONCLUSION] Our results highlight CDKN1B as a prognostic biomarker to guide CDK4/6-targeted therapy and a predictor of endocrine resistance in HR + /HER2- breast cancer.
[METHOD] We performed integrated genomic, transcriptomic, and functional analyses of 186 HR + /HER2-tumors (88 sensitive, 98 resistant), to identify key drivers of endocrine hormone therapy resistance, Findings were validated functionally using in-vitro and in-vivo models.
[RESULTS] We identify frequent CDKN1B (p27) loss-of-function mutations or deletions as a key and clinically actionable driver of endocrine resistance. CDKN1B knockdown in cell lines induces resistance to tamoxifen and fulvestrant, while its restoration re-sensitizes resistant cells. Importantly, CDKN1B-deficient tumors remain responsive to CDK4/6 inhibition, in vitro and in vivo. Immunohistochemistry and transcriptomic analysis of clinical cohorts (n = 138) and TCGA-METABRIC data (n = 1398) identify low p27 as an independent predictor of early relapse and poor survival.
[CONCLUSION] Our results highlight CDKN1B as a prognostic biomarker to guide CDK4/6-targeted therapy and a predictor of endocrine resistance in HR + /HER2- breast cancer.
같은 제1저자의 인용 많은 논문 (5)
- Multitarget docking and molecular enumeration reveal DdpMPyPEPhU as a potent modulator of cell cycle, glucocorticoid, and estrogen signalling in breast cancer.
- Identification of non-oncology drugs with activity against inflammatory and triple-negative breast cancer cell lines.
- Machine learning for genomic profiling and drug discovery in personalised lung cancer therapeutics.
- Comparative outcomes of treatment modalities in nonagenarians with nonmetastatic pancreatic adenocarcinoma.
- Radiofrequency Ablation of Cervical Thyroid Cancer Metastases-Experience of Endocrinology Practices in the United States.